603983.SHG Guangdong Marubi Biotechnology Co
- Market cap
- CNY 9.98B
- P/E
- 71.1x
- P/B
- 2.76x
- ROE
- 5.4%
- Dividend yield
- 3.02%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603983.SHG undervalued?
Graham number603983.SHG trades 195.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Guangdong Marubi Biotechnology Co fundamental analysis
No fundamental analysis for Guangdong Marubi Biotechnology Co yet.
Guangdong Marubi Biotechnology Co stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Guangdong Marubi Biotechnology Co
Guangdong Marubi Biotechnology Co., Ltd. engages in the research and development, design, production, sale, and service of various cosmetics in China. The company offers eye care, skincare, cleansing, and beauty and other products. It sells its products under the Marubi, Lianhuo, Chunji, and Passional Lover brands. The company was founded in 2002 and is based in Guangzhou, China.
Full company profileGuangdong Marubi Biotechnology Co financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Guangdong Marubi Biotechnology Co annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.21B | 1.35B | 1.58B | 1.80B | 1.74B | 1.79B | 1.73B | 2.23B | 2.97B | 3.46B | 2.98B |
| Gross Profit | 818M | 917M | 1.07B | 1.22B | 1.15B | 1.13B | 1.17B | 1.56B | 2.18B | 2.57B | 2.18B |
| Operating Income | 260M | 366M | 484M | 613M | 573M | 299M | 207M | 319M | 381M | 254M | 95.1M |
| EBITDA | 258M | 349M | 427M | 541M | 451M | 232M | 154M | 192M | 361M | 362M | 222M |
| Net Income | 232M | 312M | 415M | 515M | 464M | 248M | 174M | 259M | 342M | 247M | 183M |
| EPS | 0.64 | 0.87 | 1.15 | 1.28 | 1.16 | 0.62 | 0.43 | 0.65 | 0.85 | 0.62 | 0.46 |
| Balance Sheet | |||||||||||
| Total Assets | 1.48B | 1.60B | 2.12B | 3.44B | 3.80B | 3.76B | 4.09B | 4.45B | 5.06B | 4.61B | 4.56B |
| Total Liabilities | 648M | 643M | 735M | 766M | 794M | 603M | 839M | 1.04B | 1.62B | 1.22B | 1.14B |
| Shareholders' Equity | 828M | 960M | 1.38B | 2.67B | 2.98B | 3.08B | 3.19B | 3.35B | 3.38B | 3.33B | 3.36B |
| Cash & Short-term Investments | 941M | 1.10B | 1.56B | 2.90B | 2.49B | 1.54B | 1.51B | 2.12B | 2.43B | 1.25B | 1.28B |
| Total Debt | 20.6M | - | - | - | 107M | 19.5M | 270M | 255M | 792M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 213M | 356M | 517M | 466M | 362M | -7.48M | 48.4M | 338M | 301M | 274M | - |
| Capital Expenditure | 6.62M | 6.39M | 11.3M | 6.42M | 749M | 117M | 111M | 254M | 316M | 205M | 179M |
| Free Cash Flow | 207M | 350M | 505M | 459M | -387M | -125M | -62.5M | 84.0M | -15.8M | 68.6M | -233M |
| Ratios | |||||||||||
| ROE | 28.0% | 32.5% | 30.2% | 19.3% | 15.6% | 8.0% | 5.5% | 7.8% | 10.1% | 7.4% | 5.4% |
| ROA | 15.7% | 19.5% | 19.6% | 15.0% | 12.2% | 6.6% | 4.3% | 5.8% | 6.7% | 5.4% | 4.0% |
| Net Profit Margin | 19.2% | 23.1% | 26.4% | 28.6% | 26.6% | 13.9% | 10.1% | 11.7% | 11.5% | 7.1% | 6.1% |
| Debt to Equity | 0.02x | - | - | - | 0.04x | 0.01x | 0.08x | 0.08x | 0.23x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Guangdong Marubi Biotechnology Co dividends
- Dividend yield
- 3.02%
- Forward dividend
- 0.50 CNY
- Payout ratio
- 121.7%
- Ex-dividend date
- Jul 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 301M | 0.75 | 121.7% |
| 2024 | CNY 313M | 0.78 | 91.7% |
| 2023 | CNY 106M | 0.27 | 40.9% |
| 2022 | CNY 76.2M | 0.19 | 43.7% |
| 2021 | CNY 142M | 0.35 | 57.2% |
| 2020 | CNY 157M | 0.39 | 33.8% |
| 2019 | CNY 157M | 0.39 | 30.5% |
| 2018 | CNY 157M | 0.43 | 37.8% |
| 2017 | CNY 180M | 0.50 | 57.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Guangdong Marubi Biotechnology Co
- Insiders 80.93%
- Institutions 4.59%
- Public & others 14.48%
- Shares outstanding 401M
- Free float 77.0M
Guangdong Marubi Biotechnology Co company profile
- Company name
- Guangdong Marubi Biotechnology Co
- Ticker
- 603983.SHG
- ISIN
- CNE100003M51
- Exchange
- Shanghai Stock Exchange
- Sector
- Consumer Defensive
- Industry
- Personal Care Products
- Employees
- 1,380
- Fiscal year end
- December
- Address
- Marubi Building, Guangzhou, China, 510308
- Phone
- 400 830 4000
- Website
- marubi.cn
About Guangdong Marubi Biotechnology Co
Guangdong Marubi Biotechnology Co., Ltd. engages in the research and development, design, production, sale, and service of various cosmetics in China. The company offers eye care, skincare, cleansing, and beauty and other products. It sells its products under the Marubi, Lianhuo, Chunji, and Passional Lover brands. The company was founded in 2002 and is based in Guangzhou, China.
Guangdong Marubi Biotechnology Co management
5- Mr. Huaiqing SunChairman & CEO · born 1969
- Mr. Kaihui WangCFO & Director · born 1971
- Mr. Lingchun ZengChief Marketing Officer & Director · born 1978
- Ms. Di ChengBoard Secretary · born 1984
- Dan HuangHead of Accounting Department & Accounting Supervisor